Noxopharm White Paper

a August 2021 A first-in-class selective modulator of the sphingomyelin pathway A drug being developed as a treatment for a wide range of cancers and as a treatment for cytokine release syndrome Veyonda® Disclaimer: Veyonda is currently not approved in Australia or any other country